Coppell Advisory Solutions’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-16
Closed -$5.59M – 518
2026
Q2
$5.59M Buy
+16
New +$378 0.46% 39
2024
Q3
– Sell
-58
Closed -$1.66K – 1941
2024
Q2
$1.66K Buy
+58
New +$1.65K ﹤0.01% 1411

Other funds holding PCRX

Coppell Advisory Solutions's PCRX Position: Q3 2026 in Review

Coppell Advisory Solutions sold out of Pacira BioSciences (PCRX) in Q3 2026, closing a stake of 16 shares — an estimated $5.59M sold.

Coppell Advisory Solutions first reported a position in PCRX in Q2 2024 and held it in 2 quarters. The position peaked at $5.59M in Q2 2026. 258 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • Coppell Advisory Solutions reported no remaining Pacira BioSciences position as of Q3 2026 after selling out during the quarter.
  • Coppell Advisory Solutions sold 16 Pacira BioSciences shares in Q3 2026, an estimated $5.59M.
  • Coppell Advisory Solutions first reported a position in Pacira BioSciences in Q2 2024 and held it in 2 quarters.
  • Coppell Advisory Solutions's Pacira BioSciences position peaked at $5.59M in Q2 2026.
  • 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Coppell Advisory Solutions's 13F filing for Q3 2026, filed 16 Nov 2026.